BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 3, 2017
View Archived Issues
Orexo signs asset purchase agreement with Gesynta for OX-MPI program
Read More
Nohla Therapeutics obtains CIRM grant to support development of cell therapy for AML
Read More
MicroRNA expression profile identified for kidney antibody-mediated rejection
Read More
Regeneron Pharmaceuticals establishes agreement with BARDA
Read More
Opiant and Titan to develop product for opioid use disorder
Read More
Seres Therapeutics reports topline results from phase Ib study of SER-287 in ulcerative colitis
Read More
First-in-human study shows utility of [11C]-preladenant in imaging brain adenosine receptors
Read More
FDA grants orphan drug designation to Stealth BioTherapeutics' elamipretide for PMM
Read More
Janssen applies for U.S. approval of Invokana for CV events in patients with type 2 diabetes
Read More
FDA accepts Avycaz sNDA for priority review
Read More
Dipeptidyl peptidase 1 inhibitor AZD-7986 affects neutrophil serine proteases in humans
Read More
FDA not to hold committee meeting to discuss Rigel's NDA for fostamatinib
Read More
Vanderbilt University describes new Mcl-1 inhibitors
Read More
Ancureall Biomedical Technology identifies novel FLT3-ITD inhibitors
Read More
Bayer divulges novel PGF receptor antagonists
Read More
Novel PPAR-gamma agonists developed at Zhejiang Xuchen Pharmaceutical Technology
Read More
Exerkine creates novel neuropeptide gene therapy
Read More
KSQ Therapeutics secures USD 76 million to support CRISPRomics-powered drug discovery
Read More
bluebird bio initiates phase I study of bb-21217 in multiple myeloma
Read More
Astellas initiates phase I study of immune checkpoint inhibitor ASP-8374 in solid tumors
Read More
Novartis studies LLG-783 in patients with peripheral artery disease and intermittent claudication
Read More
Aptevo completes sale of three hyperimmune products to Saol Therapeutics
Read More
Topline phase II/III results do not support continued development of trigriluzole for SCA
Read More
CYP3A4 interactions with sodium channel blocker BIIB-074 studied in healthy subjects
Read More
FDA awards breakthrough therapy designation to Adcetris for Hodgkin's lymphoma
Read More
Sato and Eisai agree to copromote fosravuconazole in Japan
Read More
First patient dosed in phase I study of Pieris Pharmaceuticals' PRS-343
Read More
Takeda reports results from Japanese phase III trial of relugolix in uterine fibroids
Read More
U.S. BARDA announces agreements to purchase four Ebola countermeasures
Read More